Vicilin GC72-A Antibody

What is Vicilin GC72-A and what is its biological significance?

Vicilin GC72-A is a storage protein found in glandless cottonseed (Glc) with a molecular weight of approximately 71 kDa. It belongs to the vicilin family of seed storage proteins and contains cupin domains, which are characteristic of this protein family. The biological significance of Vicilin GC72-A lies in its structural similarity to known food allergens, particularly the Ara h 1 peanut allergen, suggesting potential cross-reactivity in allergic individuals. Additionally, it serves as a nitrogen reservoir during seed germination and early seedling growth. Vicilin GC72-A is abundant in cottonseed, representing between 4.07% and 23.91% of the water-soluble protein fraction, depending on the extraction condition . This protein has gained research attention not only for its allergenic properties but also as a potential source of bioactive peptides with various health-promoting activities .

How does Vicilin GC72-A compare structurally to other vicilin proteins?

Vicilin GC72-A shares structural similarities with other vicilin proteins, particularly those found in legumes. Like other vicilins, it contains cupin domains (interpro signatures IPR006045, IPR014710, and IPR011051) that feature a characteristic β-barrel structure. These domains are evolutionarily conserved and contribute to the protein's allergenicity and bioactive peptide potential. In cottonseed, Vicilin GC72-A exists alongside another vicilin protein called C72. Both proteins have similar molecular weights (GC72-A at 71 kDa and C72 at 70 kDa) and share sequence homology, but they differ in their abundance patterns across different extraction fractions . The structural similarity to the Ara h 1 peanut allergen is particularly notable, as demonstrated by immunoblot assays showing cross-reactivity with anti-Ara h 1 antibodies . This structural homology explains the observed cross-recognition by IgE antibodies from individuals with peanut and tree nut allergies.

What are the recommended applications for Vicilin GC72-A antibodies in research?

Vicilin GC72-A antibodies are primarily used in enzyme-linked immunosorbent assays (ELISA) and Western blot (WB) applications for the detection and quantification of Vicilin GC72-A in various samples . In ELISA applications, these antibodies can be used to detect the presence of Vicilin GC72-A in food samples, particularly those containing cottonseed derivatives. This is especially important for allergen detection in food products. In Western blot applications, the antibodies help validate the identity of purified Vicilin GC72-A proteins and assess their integrity after various experimental treatments, such as enzymatic digestion or heat processing. These antibodies may also be useful in immunohistochemistry to localize Vicilin GC72-A within cottonseed tissues, although this application isn't explicitly mentioned in the search results. For all applications, proper validation and optimization are necessary, including determining appropriate antibody dilutions and establishing detection limits for the specific experimental system being used .

How should researchers design experiments to study Vicilin GC72-A's allergenic potential?

Researchers studying Vicilin GC72-A's allergenic potential should implement a multi-faceted experimental approach. Begin with immunological assays such as immunoblotting using anti-Ara h 1 antibodies to evaluate cross-reactivity, as demonstrated in previous research that showed C72 and GC72A were recognized by three anti-Ara h 1 antibodies . For human allergic response assessment, conduct ELISA testing using purified native C72 and GC72A proteins with sera from individuals with confirmed peanut or tree nut allergies, alongside appropriate controls (such as dust mite allergic sera). Statistical analysis should employ ANOVA (p≤ 0.01) followed by Tukey honestly significant difference (HSD) to determine significant IgE binding compared to controls .

Additionally, prepare both native and recombinant forms of the protein, as research has shown differential recognition patterns. In previous studies, only a subset of sera that recognized native proteins also bound to recombinant forms (3 of 13 for C72 and 4 of 13 for GC72A) . To assess digestibility, which affects allergenic potential, perform in vitro simulated gastric fluid (SGF), simulated intestinal fluid (SIF), and combined gastrointestinal fluid (GI) assays using standardized protocols with appropriate enzyme concentrations. Finally, conduct computational analyses to predict potential allergenic epitopes through sequence and structural comparisons with known allergens.

What are the optimal methods for purifying native Vicilin GC72-A?

The optimal purification of native Vicilin GC72-A from cottonseed involves a sequential extraction and chromatography approach. While the search results don't detail the complete purification protocol, we can infer from standard protein purification methods and the available information that the process likely includes the following steps:

First, prepare a crude extract from glandless cottonseed by homogenizing the seed meal in an appropriate buffer (typically phosphate-buffered saline or Tris buffer). After centrifugation to remove insoluble materials, perform an initial fractionation using ammonium sulfate precipitation. The precipitated proteins can then be resuspended and subjected to sequential chromatography steps. Ion exchange chromatography (typically using a DEAE or Q-Sepharose column) would separate proteins based on charge, followed by size exclusion chromatography to isolate proteins of the appropriate molecular weight (approximately 71 kDa for Vicilin GC72-A) .

The purified protein should be verified by SDS-PAGE, Western blotting with specific antibodies, and mass spectrometry to confirm identity and purity. For mass spectrometry validation, tryptic digestion followed by LC-MS/MS analysis can be performed, comparing the results against a Gossypium hirsutum protein database . This approach ensures both the identity and purity of the isolated Vicilin GC72-A protein for subsequent experimental applications.

How can researchers produce recombinant Vicilin GC72-A for experimental studies?

Recombinant Vicilin GC72-A can be produced using bacterial expression systems following established molecular biology techniques. Based on the search results, researchers have successfully expressed Vicilin GC72-A in Escherichia coli. The process begins with gene amplification from cottonseed (Gossypium hirsutum) cDNA using PCR with primers containing appropriate restriction sites (such as NdeI and HindIII) . The amplified gene is then cloned into an expression vector that allows for the addition of an amino-terminal 6×-histidine tag to facilitate purification.

For protein expression, the verified plasmid is transformed into E. coli BL21 Star (DE) cells, and protein production is induced with 0.5 mM isopropyl-β-d-thiogalactopyranoside (IPTG) for 16 hours at 15°C . These lower temperature conditions help minimize inclusion body formation and improve the yield of soluble protein. The recombinant protein is then purified under denaturing conditions using nickel affinity chromatography, taking advantage of the His-tag's affinity for nickel ions.

The purified protein should be verified by SDS-PAGE, trypsin peptide analysis, and intact mass analysis to confirm identity and purity. For storage, the protein can be aliquoted and maintained in a buffer containing 50 mM Tris–HCl, 150 mM NaCl, 0.5 M l-arginine, 10% glycerol, pH 8.0 at −80°C . This storage buffer helps maintain protein stability and prevents aggregation during freeze-thaw cycles.

What is known about the epitope mapping of Vicilin GC72-A and its implications for allergenicity research?

The fact that only a subset of peanut- and tree-nut-allergic sera that recognized native Vicilin GC72-A also bound to the recombinant form (4 of 13 for GC72A) further supports this hypothesis . This has important implications for allergenicity research, as it suggests that both linear and conformational epitopes should be considered when evaluating the allergenic potential of Vicilin GC72-A.

For comprehensive epitope mapping, researchers should employ both computational approaches (sequence alignment, structural modeling) and experimental techniques such as epitope mapping using overlapping peptides, alanine scanning mutagenesis, and X-ray crystallography of antibody-allergen complexes. Understanding the specific epitopes recognized by allergic individuals' IgE could lead to the development of hypoallergenic variants or targeted immunotherapies.

How does the digestibility of Vicilin GC72-A affect its allergenic potential compared to other food allergens?

In vitro simulated digestion studies indicate that Vicilin GC72-A and other glandless cottonseed proteins are readily digested under conditions mimicking the human digestive system . This digestibility profile is an important factor in assessing allergenic potential, as proteins that resist digestion are more likely to reach the intestinal mucosa intact, where they can trigger allergic responses.

The digestibility of Vicilin GC72-A can be evaluated using simulated gastric fluid (SGF) containing pepsin and simulated intestinal fluid (SIF) containing pancreatin, as well as sequential gastrointestinal (GI) digestion combining both enzymes . While specific digestibility kinetics aren't detailed in the search results, the information suggests that Vicilin GC72-A is more susceptible to digestion than some other food allergens like Ara h 1, which is known to have digestion-resistant epitopes.

What bioactive peptides can be derived from Vicilin GC72-A and what are their potential applications?

Vicilin GC72-A represents a promising source of bioactive peptides with diverse functional properties. In silico analysis has revealed that C72, GC72A, and other cupin domain-containing proteins from cottonseed can yield peptides with several bioactivities . Specifically, these proteins demonstrate potential for producing peptides with antioxidant activity, angiotensin-converting enzyme (ACE) inhibition properties (relevant for blood pressure regulation), and anti-diabetic effects.

Previous research has confirmed that cottonseed protein hydrolysates produced by enzymatic treatment with proteases from Aspergillus niger or Alcalase contain antioxidant peptides, with many derived specifically from the C72 and GC72A vicilin proteins . The frequency of bioactive fragments in these proteins is notably high, with cupin domain-containing proteins showing ∑A values in the range of 1.4099–1.6102, which is higher than previously reported for similar domains in peanut and tree nut allergens (1.2749–1.3833) .

How can researchers optimize protocols for analyzing the cross-reactivity between Vicilin GC72-A and known allergens?

Optimizing protocols for cross-reactivity analysis between Vicilin GC72-A and known allergens requires a systematic approach combining immunological and biochemical techniques. Begin with protein preparation: purify both native and recombinant Vicilin GC72-A to high homogeneity, confirmed by SDS-PAGE and mass spectrometry . For immunoblot assays, establish optimal protein loading concentration, transfer conditions, and blocking parameters. Use multiple anti-Ara h 1 antibodies (both monoclonal and polyclonal) to ensure comprehensive epitope detection, as previous research successfully demonstrated cross-reactivity with three different anti-Ara h 1 antibodies .

For ELISA testing, optimize coating concentration (5 μg protein was effective in previous studies) and incubation conditions (overnight at 4°C followed by blocking with 1% BSA in PBST) . When testing with human sera, include appropriate controls: dust mite allergic sera serve as negative controls, while peanut-allergic sera provide positive reference. Statistical analysis should employ ANOVA (p≤ 0.01) with Tukey HSD to determine significant binding above background .

To address conformational versus linear epitopes, compare results between native and recombinant proteins, and consider including denatured/reduced samples. Peptide inhibition studies can further define cross-reactive epitopes: pre-incubate sera with peptides from Ara h 1 before testing binding to Vicilin GC72-A. Finally, incorporate digestibility assessment using standardized in vitro digestion protocols to evaluate whether cross-reactive epitopes survive gastrointestinal processing .

What are the optimal storage and handling conditions for Vicilin GC72-A antibodies?

According to the product information available, Vicilin GC72-A antibodies should be stored at -20°C or -80°C upon receipt . Researchers should avoid repeated freeze-thaw cycles as these can degrade the antibody and reduce its effectiveness. The antibody is typically supplied in liquid form containing 50% glycerol with 0.03% Proclin 300 as a preservative in 0.01M PBS at pH 7.4 . This formulation helps maintain antibody stability during storage.

For routine use, it's advisable to prepare small working aliquots of the antibody to minimize freeze-thaw cycles. When handling the antibody, maintain cold chain practices and use sterile techniques to prevent contamination. For dilutions, use fresh, sterile buffers appropriate for the intended application (such as PBST for ELISA). The specific dilution factors would depend on the application and should be optimized for each experimental setup, though the manufacturer's recommendations provide a useful starting point.

Before each use, gently mix the antibody solution without vortexing, as excessive agitation can lead to protein denaturation and aggregation. After use, promptly return the antibody to appropriate cold storage. For long-term storage beyond the immediate research period, the -80°C storage option is preferable to maximize shelf-life and maintain antibody activity .

What quality control measures should be implemented when working with Vicilin GC72-A antibodies?

Implementing robust quality control measures when working with Vicilin GC72-A antibodies ensures reliable and reproducible research outcomes. Begin with antibody validation: verify specificity through Western blotting against both purified Vicilin GC72-A and cottonseed protein extracts, confirming a single band at the expected molecular weight of approximately 71 kDa . Include positive controls (purified Vicilin GC72-A) and negative controls (unrelated proteins) in each experimental run.

For ELISA applications, establish standard curves using purified Vicilin GC72-A protein to determine detection limits and linear range. Perform cross-reactivity testing against related proteins (such as Vicilin C72) to assess specificity within the vicilin family . When using the antibody for the first time or starting a new lot, conduct dilution series experiments to optimize antibody concentration for each specific application.

Maintain detailed records of antibody source, lot number, concentration, and performance characteristics. Store reference samples of well-performing antibody lots for batch-to-batch comparisons. Implement regular performance monitoring through consistent use of control samples across experiments. For collaborative research, establish standardized protocols for antibody handling and application to ensure comparable results across different laboratories. Finally, consider periodic validation of antibody activity if stored for extended periods, as antibody performance can diminish over time even under optimal storage conditions .

How can Vicilin GC72-A research contribute to allergen detection and management in food products?

Vicilin GC72-A research has significant potential to advance allergen detection and management in food products containing cottonseed derivatives. As glandless cottonseed gains popularity as a food ingredient due to its nutritional properties, understanding the allergenic potential of its constituent proteins becomes increasingly important. The demonstrated cross-reactivity between Vicilin GC72-A and the Ara h 1 peanut allergen, with approximately 50% of peanut or tree-nut-allergic sera recognizing this protein, highlights the need for careful consideration in food safety practices .

Development of sensitive and specific immunoassays using Vicilin GC72-A antibodies could enable food manufacturers to accurately detect and quantify this potential allergen in raw materials and finished products. This would be particularly valuable for ensuring proper allergen labeling and preventing cross-contamination in production facilities. The availability of commercial antibodies specific to Vicilin GC72-A facilitates the implementation of such testing methods .

Furthermore, understanding the specific epitopes responsible for cross-reactivity could lead to improved risk assessment models for predicting potential allergic reactions in sensitive individuals. This knowledge could also inform the development of processing techniques that might reduce allergenicity while preserving nutritional value. For clinical applications, identifying Vicilin GC72-A as a cross-reactive allergen could improve diagnostic approaches for individuals with peanut or tree nut allergies who might also react to cottonseed products .

What are the emerging research directions for exploring Vicilin GC72-A's bioactive peptides?

Emerging research directions for Vicilin GC72-A's bioactive peptides are expanding beyond traditional allergenicity studies to explore beneficial health applications. The in silico analysis revealing that Vicilin GC72-A can yield peptides with antioxidant activity, ACE inhibition properties, and anti-diabetic effects opens multiple promising research avenues . One key direction involves optimizing enzymatic hydrolysis conditions to maximize the release of bioactive peptides, as research indicates that gastrointestinal digestion alone may result in limited bioactive peptide release (∑AE values of 0.0958–0.1753) .

Researchers should focus on identifying and characterizing specific peptide sequences responsible for each bioactivity through fractionation techniques coupled with bioactivity assays and mass spectrometry. Structure-function relationship studies would help elucidate the molecular mechanisms underlying these bioactivities, potentially enabling the design of enhanced peptides with greater potency or stability.